In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

September 23, 2011 (London, United Kingdom) — Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban (Xarelto, Bayer) in Europe. The EMA's ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

Study finds apixaban’s safety preferable over other anticoagulant medication following assessment of respective bleeding ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...